Last updated: 11/03/2018 11:52:39
Phase 1 study of Levocetirizine
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A single blind, randomized, single oral dose study to compare the oral disposition of levocetirizine when given alone (5mg) or as the racemate (cetirizine 10mg), and to investigate the safety and tolerability and the pharmacokinetics of levocetirizine and cetirizine, following a single dose in healthy Japanese male subjects
Trial description: This is a single center, single blind, single dose, randomized, partial cross-over study to confirm bioequivalence between levocetirizine and cetirizine.
Primary purpose:
Prevention
Trial design:
Crossover Assignment
Masking:
Single (Participant)
Allocation:
Randomized
Primary outcomes:
AUC0-48 of levocetirizine
Timeframe: predose,0.25,0.5,1,1.5,2,3,4,6,9,12,16,24,36, 48 hours post-dose
Cmax of levocetirizine
Timeframe: predose,0.25,0.5,1,1.5,2,3,4,6,9,12,16,24,36, 48 hours post-dose
Secondary outcomes:
Number of Adverse events
Timeframe: predose,1,24 48 hours post-dose
Changes in clinical laboratory tests
Timeframe: predose,24,48 hours post-dose
Changes in vital signs
Timeframe: predose,1,24,48 hours post-dose
Changes in 12-lead ECG.
Timeframe: predose,1,24,48 hours post-dose
Interventions:
Enrollment:
20
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Hiroko Ino, Shigeru Nohda, Shuji Miki, Kastutoshi Hara, Toshiyasu Hirama. Comparison of levocetirizine pharmacokinetics, following a single dose of levocetirizine alone or as cetirizine in Japanese healthy male volunteers . [Jpn J Clin Pharmacol Therapeut]. 2010;41(6):309.
Medical condition
Dermatitis
Product
levocetirizine
Collaborators
Not applicable
Study date(s)
March 2008 to April 2008
Type
Interventional
Phase
1
Participation criteria
Sex
Male
Age
20 - 64 years
Accepts healthy volunteers
Yes
- 1.Japanese healthy male subjects aged between 20 and 64 years of age inclusive.
- Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory studies, and other tests.
- 1.The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
- 2.The subject has an allergy for any drug or idiosyncrasy.
Inclusion and exclusion criteria
Inclusion criteria:
- 1.Japanese healthy male subjects aged between 20 and 64 years of age inclusive. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory studies, and other tests. 2.Body weight ≥ 50 kg and BMI within the range 18.50-25.00 kg/m2 inclusive. 3.Non-smokers (at least 6 months). 4.Clinical laboratory tests data obtained at screening meet the following: AST(GOT), ALT(GPT), total-bilirubin, BUN, creatinine, uric acid,: below the upper normal range 5.Normal 12-lead EGC finding at screening; QTc interval <450msec 6.Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion criteria:
- 1.The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator. 2.The subject has an allergy for any drug or idiosyncrasy. 3.The subject has a history of allergic rhinitis. 4.The subject has a history or presence of clinically significant gastrointestinal, hepatic or renal disease or other condition known to interfere with absorption, distribution, metabolism or elimination of drugs. 5.The subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational drug or device. 6.The subject has participated in a clinical study with an investigational or a non-investigational drug or device during the previous 4 months. 7.The subject has a history or current conditions of drug abuse or alcoholism. 8.History of regular alcohol consumption exceeding on average, 14 drinks/week (1 drink = 150mL of wine or 360mL of beer or 45mL of 80 proof distilled spirits). 9.The subject is positive for urine drug screening. 10.The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody. 11.The subject has donated a unit of blood ">400mL" within the previous 4 months or ">200mL" within the previous 1 month.
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2008-30-04
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 111580 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website